~~<i id='CEF8EF013D'><strike id='CEF8EF013D'><tt id='CEF8EF013D'><pre id='CEF8EF013D'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：knowledge 2025-09-28 00:10:29 Page View：3499

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

explore

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

'Brian's Song' at 50 still offers lessons about cancer for today

BrianPiccolo(41)oftheChicagoBearsbeingstoppedbyKarlKassulke(29)oftheMinnesotaVikingstwoseasonsbefore

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Google's generative AI to analyze medical images — and talk to docs

NOAHSEELAM/AFPviaGettyImagesGoogle’sgenerativeAIsystemproveditcananswermedicalexamquestions.Butnowth